A problem solved by the following website.
https://sci-hub.wf
I have to say the abstract of this paper has done more damage to Race than almost any other paper. Everyone reads the abstract and then dismisses bisantrene as a dud when the actual paper says bisantrene beats doxorubicin.
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-96
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
-0.005(0.30%) |
Mkt cap ! $282.9M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.64 | $46.19K | 27.75K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 8155 | $1.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 734 | 2 |
View Market Depth
| Last trade - 13.58pm 07/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |